Pfizer (NYSE: PFE) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...

Whilst it can work as an affective weight-loss drug for those who are obese, it should never be used for a short-term ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Scholar Rock is also working on a treatment that helps preserve lean muscle that is often lost during rapid weight loss by patients taking the new class of GLP-1 drugs. Scholar Rock's stock is down 45 ...

As you are likely aware, many people are using a class of drugs called GLP-1 receptor agonists for weight loss. One of the ...

Scholar Rock said on Monday its experimental drug apitegromab met the main goal of a late-stage trial in patients with a type of rare genetic disease, sending the company's shares surging in premarket ...

It feels as though just about every celebrity in Hollywood is using Ozempic - but what effect does the controversial drug ...

In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.

With a market cap of $27.1 billion, DexCom, Inc. (DXCM) is a leading medical device company, specializing in continuous ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...